Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
February 24, 2017 07:00 ET
|
Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...
Cempra Appoints Dr. David Zaccardelli as Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
December 12, 2016 09:01 ET
|
Cempra, Inc.
—Leadership changes bolster manufacturing, regulatory and commercial expertise— —Cempra founder, president and CEO, Dr. Prabhavathi Fernandes, announces retirement from the company and...
Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
June 28, 2016 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 28, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
September 18, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Two Upcoming Scientific Conferences
April 17, 2015 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...